Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lansoprazole Post-Sleeve Gastrectomy
NCT04400136Phase 1Unknown
- Sponsor
- Sapienza University of Rome
- Start
- Jul 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lansoprazole in gastroesophageal reflux disease (GERD) (3 arms), sponsored by Sapienza University of Rome. Primary endpoint: Percentage of post-operative GERD at 12 months. Status: unknown.
02
Drugs
lansoprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT04400136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04400136.